Results 81 to 90 of about 253,625 (250)

Highly Permeable CeO2 Porous Hollow Microspheres with Multilevel Gas Channels for Rapid NH3 Gas Response and Recovery Performance

open access: yesENERGY &ENVIRONMENTAL MATERIALS, EarlyView.
In this study, a series of highly permeable CeO2 porous hollow microspheres with multilevel gas channels and tunable pore sizes were first prepared via the hydrothermal method, achieving rapid response and fast recovery to ammonia gas. Fast response and recovery performance is highly significant for real‐time monitoring of NH3 gas due to the toxic and ...
Mengke Li   +11 more
wiley   +1 more source

CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial

open access: yesTrials, 2020
Background A substantial proportion of breast cancer patients develop metastatic disease, with over 450,000 deaths globally per year. Bone is the most common first site of metastatic disease accounting for 40% of all first recurrence and 70% of patients ...
Rob Coleman   +11 more
doaj   +1 more source

Recent Insights in Barium-131 as a Diagnostic Match for Radium-223: Cyclotron Production, Separation, Radiolabeling, and Imaging

open access: yesPharmaceuticals, 2020
Barium-131 is a single photon emission computed tomography (SPECT)-compatible radionuclide for nuclear medicine and a promising diagnostic match for radium-223/-224.
Falco Reissig   +8 more
doaj   +1 more source

Lead‐free halide perovskites for efficient light‐emitting devices

open access: yesFlexMat, EarlyView.
Overview of Lead‐free metal halide perovskites with different categories and optoelectronic application directions, including solid‐state lighting, light‐emitting diodes, piezoluminescence, flexible electronics, scintillators and CPL emitters. Abstract Lead halide perovskites exhibit promising optoelectronic properties for optoelectronic applications ...
Yueqi Shen   +9 more
wiley   +1 more source

Radium-223 for the treatment of patients with castration-resistant prostate cancer with bone metastases

open access: yesМедицинский совет, 2018
The development of resistance to endocrine therapy and the tumor progression in patients with prostate cancer are associated with an unfavourable prognosis.
A. D. Kaprin   +3 more
doaj   +1 more source

Alpha‐emitters and targeted alpha therapy in cancer treatment

open access: yesiRADIOLOGY, 2023
Alpha emitters are radionuclides with good pharmacological characteristics for the treatment of cancer because they decay by emitting high linear energy transfer particles.
Jiajia Zhang   +5 more
doaj   +1 more source

Radium-223-dikloridi kastraatioresistentin eturauhassyövän hoidossa : Arviointikooste [PDF]

open access: yes, 2015
Kastraatioresistentillä eturauhassyövällä tarkoitetaan tilannetta, jolloin tauti leviää, vaikka seerumin testosteronipitoisuus on kastraatiotasolla. Levinneessä eturauhassyövässä luusto on tavallisin etäpesäkkeen ilmenemispaikka.
Kiviniemi, Vesa   +2 more
core  

Osteoarthritis: An Immuno‐Inflammatory Disease‐Mechanisms of Immune Cell Dysregulation and Potential Therapeutic Strategies

open access: yesMed Research, EarlyView.
This review summarizes the immuno‐inflammatory mechanisms driving the pathogenesis of osteoarthritis (OA), extending beyond the traditional view of OA as a purely degenerative disease to incorporate immune cell infiltration, inflammatory factor release, and the formation of a chronic low‐grade inflammatory microenvironment.
Qingqiang Lei   +9 more
wiley   +1 more source

Efficacy and safety of Radium-223 therapy in castration-resistant prostate cancer with bone metastases

open access: yes, 2023
Radium-223 is a newly developed therapeutic option for the treatment of patients with castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease.
Nguyen, Long
core  

Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. [PDF]

open access: yes, 2016
BACKGROUND: Myelosuppression is common in patients with progressive castration-resistant prostate cancer and bone metastases. Radium-223 prolongs overall survival in these patients but may cause myelosuppression; understanding risk factors will improve ...
Nilsson, Sten   +40 more
core   +1 more source

Home - About - Disclaimer - Privacy